Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients

Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia. AIMS: The objective of this study was to evaluate the safety and efficacy of saroglitazar 4 mg once daily in clinical practice. METHODS: This was an observational, multicenter, single-arm study. Pa...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Indian Heart J
Main Authors: Shetty, Sadanand R., Kumar, Soumitra, Mathur, R.P., Sharma, Kamal H., Jaiswal, Ashok D.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2015
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4382542/
https://ncbi.nlm.nih.gov/pubmed/25820046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ihj.2015.02.007
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki